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Abstract: The emergence of multiple antibiotic resistant bacteria has pushed the available pool of
antibiotics to the brink. Bacterial secondary metabolites have long been a valuable resource in the
development of antibiotics, and the genus Burkholderia has recently emerged as a source of novel
compounds with antibacterial, antifungal, and anti-cancer activities. Genome mining has contributed
to the identification of biosynthetic gene clusters, which encode enzymes that are responsible for
synthesis of such secondary metabolites. Unfortunately, these large gene clusters generally remain
silent or cryptic under normal laboratory settings, which creates a hurdle in identification and
isolation of these compounds. Various strategies, such as changes in growth conditions and antibiotic
stress, have been applied to elicit the expression of these cryptic gene clusters. Although a number
of compounds have been isolated from different Burkholderia species, the mechanisms by which the
corresponding gene clusters are regulated remain poorly understood. This review summarizes the
activity of well characterized secondary metabolites from Burkholderia species and the role of local
regulators in their synthesis, and it highlights recent evidence for the role of global regulators in
controlling production of secondary metabolites. We suggest that targeting global regulators holds
great promise for the awakening of cryptic gene clusters and for developing better strategies for
discovery of novel antibiotics.
Keywords: antibiotics; biosynthetic gene clusters; Burkholderia; gene regulation; global transcriptional
regulator; MftR; ScmR; secondary metabolites
1. Introduction
A large number of antibiotics are in clinical use, and they target a variety of pathways that range
from cell wall, protein, and DNA synthesis to folate and nucleotide metabolism [1]. Over the last
decade, occurrences of multiple drug resistant bacteria have been on the rise, and the development of
new effective methods or drugs to combat such strains has become critical [2]. Studies focused on the
identification and isolation of novel natural products from microbes that are effective against pathogenic
bacteria or possess other clinical significance, e.g., anti-fungal, anti-cancer, and immunosuppressant
activities, have become a priority [3,4]. A considerable number of current pharmaceutical drugs
have been directly derived from, or inspired by, bacterial natural products or secondary metabolites.
These secondary metabolites, which are not essential for growth under normal conditions, are produced
by bacteria in response to environmental stress or host interaction and provide them with a competitive
advantage. Many bacterial species produce bioactive secondary metabolites, of which members of
the genus Streptomyces and lately the genus Burkholderia are prominent sources. Streptomyces is the
source of about 80% of the antibiotics that are produced today, which includes neomycin, kanamycin,
vancomycin, streptomycin, tetracycline, and chloramphenicol [5,6]. Proteins that are essential for the
production of these bioactive compounds are generally encoded by large cryptic gene clusters, which
remain silent under normal laboratory conditions, a circumstance that creates a hurdle in discovery
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of novel compounds [7,8]. This review article focuses on such cryptic gene clusters in the genus
Burkholderia and on potential mechanisms for eliciting their expression.
When originally coined in 1992, the genus Burkholderia comprised seven species [9]. At present,
nearly a hundred validly named Burkholderia species exist [10]. These Burkholderia species occupy diverse
ecological niches (free living, saprophytic, obligate endosymbionts, phytopathogens, opportunistic
pathogens, or obligate parasites) and they include species that can serve as biocontrol and bioremediation
agents as well as pathogens. Some Burkholderia species, mainly B. pseudomallei, B. mallei, and members
of the B. cepacia complex (Bcc), have caught attention because of their pathogenicity [11]. Genome
sequencing of Burkholderia spp., driven largely by a desire to understand virulence mechanisms,
has led to the discovery of a large number of cryptic natural product biosynthetic gene clusters [12].
The regulatory mechanism of some of these cryptic gene clusters has been studied in detail, primarily
in B. thailandensis. B. thailandensis, which is a relatively non-pathogenic strain, shares a large number
of genes with other members of the B. pseudomallei complex (Bpc), some of which are involved in
synthesis of bioactive compounds.
The B. thailandensis genome features ~22 natural product biosynthetic gene clusters [12,13].
Understanding how these gene clusters are regulated by local or global regulators (repressors or
activators) and how different stress conditions (such as oxidative stress, osmolarity stress, phosphate
starvation, and amino acid starvation) or inducing ligands can elicit gene expression is key to unlocking
the potential of these cryptic gene clusters. Here, we focus on how the gene clusters that are responsible
for encoding proteins involved in the synthesis of well-characterized bioactive compounds are regulated
by local transcription factors dedicated to a specific gene cluster and how global regulators exert control
over multiple gene clusters. Based on recent reports that a multitude of compounds are concurrently
produced under conditions such as antibiotic stress and that the corresponding gene clusters are
induced by inactivating a single transcription factor, we propose that such global regulators hold the
key to the discovery of novel compounds.
2. Bioactive Secondary Metabolites
2.1. Malleilactone
Bacterially produced cytotoxic products are an important contributor to pathogenesis during host
infection. To conserve energy, such compounds are only produced when needed and in response to
inducing signals; they are, therefore, generally not synthesized under normal laboratory conditions,
and this renders their identification and characterization particularly challenging. Malleilactone
(also identified as Burkholderic acid [14]), is a polyketide synthase (PKS)-derived cytotoxic product,
produced by species in the B. pseudomallei complex (Bpc), and it has received much attention, as it has
been shown to be essential for B. pseudomallei and B. thailandensis to cause infection in Caenorhabditis
elegans (Figure 1). Malleilactone can also inhibit growth of Gram-positive bacteria and it is cytotoxic
to cultured mammalian cells [15–17]. Proteins that are encoded by the mal gene cluster produce it
(Table 1).
In B. thailandensis, the mal cluster is an ~35 kb cryptic gene cluster with 13 open reading frames
(BTH_II2088 to BTH_II2099). The mal cluster is highly conserved in B. pseudomallei and B. mallei with
about 80–90% amino acid identity across these three species [14,15] (Figure 2A). The mal cluster has
the same gene content in B. pseudomallei, B. mallei, and B. thailandensis, except that two annotated
hypothetical genes that are upstream of malA and upstream of malC are absent in B. thailandensis.
The mal cluster is divergent from the gene encoding the transcription factor MalR.
MalR has been shown to be essential for the expression of the mal cluster, and in both B. thailandensis
and B. pseudomallei, MalR was shown to be required for the bacteria to infect C. elegans [18–21]. MalR
is an orphan LuxR, which means that no cognate LuxI acyl homoserine lactone (AHL) synthase has
been identified. The intergenic region between malR and malA contains a lux box-like region, to which
MalR likely binds, and an intact lux box is required for the expression of malA, which indicates that
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MalR functions as an activator [13,15,18,19]. Generally, LuxRs respond to either endogenously and/or
exogenously produced AHLs, but MalR does not respond to AHLs. However, the deletion of all three
luxI genes in B. pseudomallei Bp82 led to ~10-fold greater production of Malleilactone, and expression
was restored to wild type levels upon the addition of all three AHLs exogenously to the mutant culture.
This led to the inference that AHL levels indirectly regulate the production of Malleilactone [19].
As outlined below, the AHL-mediated repression is likely achieved via the global regulator ScmR
(Secondary Metabolite Regulator).
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Bioactive Compound G ne Cluster Local Regulator CellularTarget/Function
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Capistruin cap Unknown RNA Polymerase
Thailandamide tha ThaA (Orphan LuxR) Acetyl-CoA Carboxylase
Burkholdacs bhc BhcM (AraC) Histone Deacetylase
Pyoverdine pvc BTH_II2035 (LTTR)? Unknown Siderophore
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2.2. Bactobolin
Bactobolin, which is a polyketide-peptide (a C6-polyketide fused to a chlorinated hydroxy-valine
residue), is produced by B. thailandensis (Figure 1). It was initially identified and characterized
in Pseudomonas BMG13-A7 (1979 AD), where the compound was shown to have antibacterial as
well as anti-tumor effects [23]. A number of studies have been conducted in Burkholderia spp. to
understand the effect of the compound, its mechanism of action, and the genes that are involved in its
synthesis. Approximately eight structurally different Bactobolin compounds have been identified in
B. thailandensis (Bactobolin A-H) [24]. Bactobolins A-D have been tested for cytotoxicity to mammalian
cells and antibacterial activity, with compounds A and C exhibiting more antibacterial activity than
B and D. Further, there is a direct correlation between cytotoxicity and antibacterial activity [25].
The compounds seem to be particularly effective against Gram-positive bacteria. A mutational study
in B. subtilis confirmed that Bactobolin targets the ribosome, but a different site than other known
ribosome inhibitors [25]. Specifically, Bactobolin A’s biological activity derives from inhibiting protein
synthesis by binding to a site in the 50S ribosomal subunit, which displaces tRNA from the P site of the
ribosome [26].
Genes that are involved in synthesis of Bactobolin have been identified and characterized for
B. thailandensis [25,27]. It is one of the few gene clusters that include both polyketide synthase (PKS)-and
nonribosomal peptide synthetase (NRPS)-encoding genes (Figure 2B). An ~37 kb gene cluster, btaA to
btaU (BTH_II1222-BTH_II1242), which includes the LuxI-LuxR system btaI2 (BTH_II1227) and btaR2
(BTH_II1231), is involved in the synthesis and regulation of Bactobolin (Table 1) [25,27]. The gene
cluster is relatively conserved in B. pseudomallei, but not in B. mallei. The btaI2-btaR2 quorum sensing
pair is absent in B. mallei (most likely lost due to deletion of genes not required for virulence) [25,28].
The presence of the btaI2-btaR2 system in the cluster suggests that the production of Bactobolin
would be regulated in a quorum sensing-dependent manner, an inference that was confirmed by the
generation of a quorum sensing-defective mutant [29]. That BtaI2 and BtaR2 control the production of
Bactobolin has been established while using the btaR2 mutant, which showed no antibiotic activity
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against Gram-positive bacteria. It is interesting to note that btaR2 could also be regulated by the
product of BtaI3 [27]. As discussed below, the expression of genes encoding BtaR2 and BtaI2, and
therefore the bta gene cluster, is under the control of the global regulators ScmR and MftR (Major
Facilitator Transport Regulator). Moreover, the production of Bactobolin has been suggested to be
influenced by temperature, as its production was higher when B. thailandensis was grown at 30 ◦C as
compared to 37 ◦C [25].
2.3. Capistruin
Capistruin belongs to the family of lasso peptides. Lasso peptides are bioactive peptides, which are
ribosomally synthesized and post-translationally modified. They are characterized by an N-terminal
macrolactam ring through which a C-terminal peptide tail is threaded [30–32]. The first lasso peptide,
Anantin, was discovered in 1991 from a strain of Streptomyces coerulescens [33]. Capistruin from
B. thailandensis was the first lasso peptide to be identified based on a genome-mining approach.
This approach has since led to the more efficient identification of lasso peptides, and about 50 lasso
peptides have been discovered so far. They have been classified into class I (which contains two
disulfide bonds), class II (the most abundant type, which has no disulfide bonds, but the topology is
held by steric hindrance), and classes III and IV (which both contain one disulfide bond that connects
the ring to the tail or is within the tail region, respectively) [34]. Capistruin belongs to class II and it is
similar to E. coli MccJ25 (Microcin J25; Figure 1).
The mature Capistruin is a 19 amino acid peptide (excised from a 47 amino acid precursor), in which
the N-terminal 9 residues form the macrolactam ring through which the 10-residues long C-terminal
tail is threaded [30,35,36]. Unlike other antibacterial compounds, Capistruin from B. thailandensis is
effective against closely related Burkholderia and Pseudomonas strains [36]. This leads to the suggestion
that Capistruin-producing Burkholderia species either encode an immunity protein or feature some
modification of the target. Capistruin and Microcin J25 biological activity is due to their ability to
inhibit RNA polymerase (RNAP), although for Microcin J25, the over-production of reactive oxygen
species (ROS) through a possible secondary target has also been suggested [37–39]. Microcin J25 and
Capistruin share the RNAP secondary channel as their binding site. Although Capistruin binds to
E. coli RNAP as effectively as Microcin J25 in vitro, a nearly 10-fold higher concentration of Capistruin is
required for inhibiting E. coli growth. Similarly, Microcin J25 can bind Pseudomonas RNAP as effectively
as Capistruin, which inhibits Pseudomonas and Burkholderia growth, but no such inhibitory effect was
seen with Microcin J25 [35,36]. A recently discovered lasso peptide, named Citrocin, which was isolated
from Citrobacter pasteurii and Citrobacter braakii, showed similar effect; the lasso peptide was nearly
100-fold more potent as an RNAP inhibitor compared to Microcin J25, but a higher concentration of
Citrocin was required to inhibit E. coli growth when compared to Microcin J25 [40]. Despite having the
same functional target, the effect of the compounds seems to be species-specific. The most likely reason
for this species specificity is a variation in cellular uptake/export [35]. Another plausible cause could be
a variation in how the compounds inhibit RNAP. The crystal structure of Microcin J25 and Capistruin
in complex with RNAP has revealed that Microcin J25 binds within the active site of RNAP, which
limits or prevents access to NTPs, and its inhibition of RNAP is partially competitive with respect
to NTP binding. This is not the case for Capistruin, which binds further away from the active site,
its inhibition is partially non-competitive with NTP binding, and it lowers the rate of phosphodiester
bond formation by eight-fold. This suggests that the Capistruin-mediated inhibition of RNAP catalysis
is primarily due to interference with the proper folding of the trigger loop, a mobile element within the
RNAP catalytic subunit [39].
By comparison to the E. coli MccJ25 gene cluster (mcjABCD), a similar cluster was found in
B. thailandensis and was determined to be the Capistruin biosynthetic gene cluster (capABCD; Figure 2C).
capABCD encodes (i) the capistruin precursor protein CapA (BTH_I2437a), (ii) two modifying enzymes
for converting the precursor to mature lasso peptide, a putative protease CapB (BTH_I2438) and
asparagine synthase CapC (BTH_I2439), and (iii) an ABC transporter CapD involved in export/immunity
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(BTH_I2440). CapD is most likely involved in the export of Capistruin from the cell, thereby mediating
both transport and detoxification. Overproduction of the CapD homolog McjD in E. coli was sufficient
to establish resistance against Capistruin [41]. The 4.5 kb lasso peptide gene cluster is conserved in
B. pseudomallei.
The mechanism of expression of lasso peptide biosynthetic genes is poorly understood (Table 1).
The E. coli mcjABCD was shown to be up-regulated under iron deficient conditions [42]. Similarly,
Capistruin production in Burkholderia was upregulated when cells were grown in minimal media
under heat stress (42 ◦C). Both cases can be related in terms of nutrient deficient conditions, but if
nutrient deficiency were the main trigger for expression, one would expect Capistruin production to
be higher in the stationary phase as compared to the exponential phase. However, unlike many other
secondary metabolites with antibacterial activity, Capistruin can be detected in exponential phase, and
its synthesis is arrested while transiting from late exponential to early stationary phase [36], which
suggests a different mode of regulation as compared to other biosynthetic gene clusters. While no local
regulator has been reported, Capistruin biosynthesis genes are under the control of ScmR and MftR,
as discussed below.
2.4. Thailandamide
Thailandamide, which is a linear, long-chain, unstable polyene natural product, is a fatty acid
synthesis blocker (Figure 1). It is a broad-spectrum antibiotic that has effect against both Gram-positive
and Gram-negative bacteria. The structure of three distinctive forms of Thailandamide have been
elucidated (Thailandamide A, Thailandamide B, and Thailandamide lactone). Thailandamide A is
effective against Gram-positives, but it is less effective against Gram-negative bacteria (except Neisseria
gonorrheae). It is interesting to note that a change in the E. coli cell wall structure, which increased
uptake, led to an increased efficiency of Thailandamide A. This prompted the suggestion that the
otherwise broad-spectrum activity of Thailandamide is limited by poor uptake in Gram-negative
bacteria [43]. A study involving insertional mutation for characterization of new antibiotics revealed
Thailandamide B to be the major product formed by B. thailandensis [44]; this is contrary to other
analyses, where Thailandamide A was shown to be the major product [43,45–47]. Thailandamide B
was revealed to have bactericidal activity and it was shown to be toxic to human cells as well. Since
Thailandamide is unstable, these differences might derive from variations in the extraction techniques;
alternatively, mutations in genes encoding regulatory factors could lead to variations in the types of
Thailandamide produced. For example, Thailandamide lactone, which was only detected in cells in
which the tha gene cluster was highly active, displayed moderate anti-proliferative activity against
tumor cell lines [46].
B. subtilis is sensitive to Thailandamide, and it was shown that a mutation in the accA gene, which
encodes acetyl-CoA carboxylase, conferred resistance against Thailandamide A. Similarly, a single base
mutation in accA was found in Thailandamide B-resistant Salmonella mutants. Further, in B. subtilis,
over-expression of mutant AccA was sufficient to relieve the Thailandamide-induced inhibition. Thus,
the cellular target for Thailandamide was suggested to be AccA protein or the AccA/AccD complex,
which is involved in the first committed step of fatty-acid biosynthesis [43,44].
The B. thailandensis gene locus BTH_II1662-1681 encodes proteins that are involved in the synthesis
of Thailandamide (BTH_II1662-1676), resistance (BTH_II1679), and regulation of its production
(BTH_II1681/ThaA; Figure 2D). thaC or accA-2 is responsible for resistance against Thailandamide
(B. thailandensis and closely related species are resistant to Thailandamide). The presence of a second
copy of accA (thaC) likely affords the resistance to Thailandamide, which further strengthens the
inference that AccA is the target for Thailandamide [43,44], as cells that express thaC are less susceptible
to Thailandamide activity. It is interesting to note that several Burkholderia spp., which lack the tha gene
cluster still encode a thaC homolog [43]. This could explain the Thailandamide resistance characteristic
of these Burkholderia spp.
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The mode of regulation of the tha biosynthetic gene cluster has not been elucidated or agreed
upon completely (Table 1). Thailandamide production seems to be regulated by more than one gene
product, and environmental cues appear to be responsible for its regulation. Under normal growth
conditions, only vanishingly small amounts of Thailandamide are produced and exclusively in the
early growth phase. The disruption of thaA (luxR5) abolished production of Thailandamide A, whereas
the disruption of the thaA promoter resulted in increased production, likely on account of increased
thaA expression. ThaA (LuxR5) has an AHL motif and is similar to LuxR regulators, but it has no
known cognate LuxI [46]. In a study that was designed to elucidate a quorum sensing-controlled
regulon in B. thailandensis, it was shown that ThaA is autoregulatory and represses thaA. Interestingly,
thaA was activated upon addition of exogenous AHLs [48]. Whether ThaA directly responds to AHL
levels or if thaA is activated by another transcription factor remains to be determined. Most likely,
ThaA activates the expression of genes that are involved in Thailandamide synthesis. As cells progress
from early growth phase, levels of AHLs increase, which should lead to an increased production of
ThaA; therefore, the observed decrease in Thailandamide production speaks to the repression of the
tha cluster by a different mechanism. As noted below, increased AHL-dependent production of ScmR
might explain such repression. Recently, it has been shown that transposon-mediated disruption of
momS (BTH_I0633) led to increased production of Thailandamide B. MomS has 66% sequence identity
to AtsR (Adhesion and Type Six Secretion System Regulator), which has been shown to be a global
regulator in B. cenocepacia [44].
2.5. Burkholdacs
Burkholdacs belong to the class of histone deacetylase (HDAC) inhibitors, which includes drugs,
such as vorinostat, romidepsin, belinostat, and panobinostat (Figure 1). HDACs are a relatively
new class of anti-cancer agents that induce death, apoptosis, and cell-cycle arrest. In eukaryotic
cells, expression of genes is regulated through chromatin remodeling. One of the mechanisms by
which such remodeling can be brought about is through either acetylation or deacetylation of lysine
residues in core histones. While HATs (histone acetyl transferases), as the name suggests, acetylate
the core histones, leading to uncoiled or less compact DNA, providing access to the transcription
machinery, HDACs remove acetyl groups leading to the condensation of DNA around histone and
repression of transcription. Thus, HDAC inhibitors prevent deacetylation, leading to an accumulation
of hyperacetylated nucleosomes and differential gene expression [49].
Burkholdacs A and B from B. thailandensis were first isolated based on the over-expression
of transcription factors linked to genes encoding secondary metabolite biosynthetic enzymes.
In B. thailandensis, the bhc gene cluster includes two adjacent operons BTH_I2357-2358 and
BTH-2359-2367, a hybrid-NRPS/PKS biosynthetic gene cluster (Figure 2E). The gene cluster has
been shown to be under control of BTH_I2369 (encoded by bhcM), an AraC family transcription
factor (Table 1) [50]. Members of the AraC/XylS family have three common regulatory functions:
carbon metabolism, stress response, and pathogenesis [51]. Most members function as transcriptional
activators, but some act as repressors or both, depending upon promoter architecture or the presence
or absence of effectors [52,53].
The above-mentioned study involving an overexpression of transcription factors within or adjacent
to NRPS/PKS gene clusters identified BhcM as an activator of the bhc gene cluster, but it did not reveal
how bhcM expression is controlled. [50]. Members of AraC/Xyls can be classified into two groups:
Either the signal receptor and regulatory function resides in same polypeptide or transcription of the
regulatory protein is controlled by another regulator, be it repressor or activator [51]. BhcM seems to
fall in the latter group, as discussed below.
2.6. Pyoverdines
Pyoverdines, fluorescent yellowish-green pigments, are the primary siderophores in P. aeruginosa
(Figure 1). Siderophores are small, metal-chelating molecules with high affinity for Fe (III), which are
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produced by almost all bacteria and generally under iron limiting conditions. The role of siderophores
becomes even more critical for pathogens that face a challenging low iron environment inside a
host [54,55]. Besides acting as iron chelators, siderophores (catecholate types) can serve an anti-oxidant
role during host-pathogen interactions [56]. Siderophores can also bind other essential metals, such as
Mn, Mo, Co, and Ni, and deliver them to the microbe [57]. Various strains of Pseudomonas secrete
different Pyoverdines, but commonalities in their structure include: (i) a fluorescent chromophore that
is quenched upon binding of Fe3+, (ii) a strain-specific peptide that interacts with Fe3+ by chelating it,
and (iii) an acyl side-chain bound to the chromophore whose functionality has not been completely
understood [58]. Pyoverdines have been shown to be involved in both acquisition of iron and as
signaling molecules for production of virulence factors [59–62]. No systematic analyses of Pyoverdine
function have been reported in B. thailandensis. However, a study was carried out to determine the
interactions between different cystic fibrosis pathogens discovered that Pyoverdine produced by
P. aeruginosa inhibited the growth of B. cenocepacia J2315 [63].
The B. thailandensis chromosome harbors a predicted Pyoverdine gene cluster (BTH_II0229-0234)
that is similar to P. aeruginosa pvcABCD (PyoVerdine Chromophore) cluster, which encodes proteins
needed to synthesize Pyoverdine [17,64]. In B. thailandensis, a convergently oriented LysR-type
transcriptional regulator (LTTR; BTH_II0235) is encoded immediately downstream of the cluster
(Figure 2F). Similarly, P. aeruginosa pvcABCD has a convergently oriented ptxR that encodes an activator
PtxR, also an LTTR. ptxR has two promoter sites, of which one is regulated in an iron dependent
manner, while the other promoter is iron-independent [65].
pvcABCD expression has been shown to be repressed by presence of iron and to be positively
regulated by the alternate sigma factor PvdS and by the activator PtxR [65,66]. A ptxR mutant
did not produce detectable Pyoverdine, even under iron deficient conditions, which suggests that
PtxR is an essential activator for expression of pvcABCD in P. aeruginosa [66]. PvdS synthesis is
repressed by another transcription factor, called Fur (Ferric uptake regulator), which utilizes Fe2+
as a corepressor [67]. A low level of iron causes the dissociation of ferrous ion from Fur, leading to
the derepression of pvdS; in turn, PvdS can possibly facilitate the expression of ptxR. B. thailandensis
encodes PtxR and several extracytoplasmic function (ECF) sigma factors, whose roles have not been
determined. A Fur homolog, BTH_I1206, is also present in B. thailandensis. Thus, the Pyoverdine gene
cluster may be similarly regulated in B. thailandensis as in P. aeruginosa (Table 1).
2.7. Ornibactin
Ornibactin, which is a tetrapeptide siderophore with an L-ornithine-D-hydroxyaspartate-L-serine-
L-ornithine backbone (Figure 1), was first identified in B. cepacia [68]. Various strains of Burkholderia
produce Ornibactin, but it has been primarily characterized in members of the Bcc. Ornibactin is
produced under iron deficient conditions and its expression is completely inhibited by the presence
of more than 15 µM of ferric iron in the media [69]. The function of Ornibactin, besides being
an iron-acquiring molecule, has been established by studies of its function in different strains of
Burkholderia. In B. cepacia, Ornibactin was shown to be critical for establishing infection in a murine
chronic respiratory infection model. Moreover, it was noted that Ornibactin was critical in adherence
and colonization [55,70]. Evolution of the role of Ornibactin was highlighted by a study that was
conducted in B. contaminans MS14, where the production of Ornibactin was shown to be critical for the
production of an antibacterial compound, which is effective against a wide range of plant-pathogenic
bacteria [71].
The Ornibactin gene cluster, orbA through orbS, has been described in B. cenocepacia J2315 (BCAL
1688-1702). The gene cluster includes a gene encoding an ECF sigma factor, orbS (BCAL 1688), whose
product OrbS has a high degree of similarity to PvdS (Figure 2G). The Ornibactin gene cluster contains
a promoter region, to which OrbS could possibly bind and thus activate the expression of the gene
cluster. Further, no production of Ornibactin was detected in an orbS mutant, suggesting that OrbS is
an essential activator (Table 1). The orbS promoter has a region to which Fur protein may bind and
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repress its expression under iron sufficiency [69]. Thus, regulation of Ornibactin synthesis by OrbS
and Fur could work in similar fashion as described for Pyoverdine.
An interesting thing to note in the case of the Ornibactin gene cluster, which is present in a large
number of Burkholderia species, is that it has conserved NRPS genes (orbI and orbJ), but contains diversity
within the genes that are involved in initiation, transport, regulation, and modification, suggesting
the possibility for differential roles and regulation across species, as exemplified by the antibacterial
activity of the B. contaminans MS14-derived Ornibactin [71]. While Ornibactin has been characterized
from members of the Bcc, members of the Bpc produce the related siderophore malleobactin, with the
biosynthetic genes being organized and regulated in a similar fashion [72].
2.8. Thailanstatin
Thailanstatin belongs to the spliceostatin class of natural products, which inhibit the spliceosome.
Four forms of the compound (Thailanstatin A-D; Figure 1) have been isolated and characterized from
B. thailandensis MSMB43 [73–75]. Alternative splicing, which is carried out by spliceosomes, generates
an abundance of protein variants, however, cancer cells exhibit increased splicing levels, mutations
in the splicing machinery, and aberrant alternative splicing. Thus, compounds that belong to the
spliceostatin class can serve as potent anti-cancer agents [73,76].
FR901464, the first natural product of the spliceostatin family, was identified in 1996 from
Pseudomonas sp. No. 2663 (subsequently, 16S rRNA sequence analysis showed the correct phylogenetic
classification to be Burkholderia sp. FERM BP-342117 [77,78]), and it was shown to have marked
anti-tumor activity [79]. As the compound is chemically unstable, a more stable methylated derivative,
Spliceostatin A, was produced. In vitro assays revealed that Thailanstatin A, which was shown to be
the most potent, could inhibit pre-mRNA splicing as efficiently as FR901464; moreover, it possesses
anti-proliferative activity and it is more chemically stable than FR901464 [73,74]. Overall, Thailanstatin
A has been shown to be less toxic to normal human cells and effective against human cancer cells lines.
Spliceostatin A and FR901464 target the splicing factor 3b (SF3b) subcomplex of the U2 small nuclear
ribonucleoprotein particle of the spliceosome, leading to the inhibition of pre-mRNA splicing and
causing pre-mRNA leakage to the cytoplasm [80].
A gene cluster with homology to the fr9 gene cluster, which encodes proteins that are required for
production of FR901464, was discovered in B. thailandensis MSMB43 and it was named the tst gene
cluster (Figure 2H); this gene cluster is not conserved in closely related species such as B. thailandensis
E264. The tst gene cluster is a 78.1 kb DNA region comprising 15 ORFs (tstA through tstR). tstA,
which is divergently oriented to the rest of the gene cluster, encodes a LuxR type transcriptional factor
with no cognate LuxI within the gene cluster (Table 1). TstA has been suggested to be involved in
the regulation of the gene cluster [73]. This genomic locus and its arrangement is very similar to the
mal gene cluster arrangement in B. thailandensis E264 suggesting that TstA could possibly serve as an
activator of the gene cluster similar to MalR. Whether TstA responds to AHL levels or any other ligand
has not been reported.
3. Global Regulators of Biosynthetic Gene Clusters
3.1. ScmR (Secondary Metabolite Regulator)
As discussed above, dedicated pathway-specific regulators control the expression of many
biosynthetic gene clusters. However, efforts to elucidate mechanisms by which cryptic biosynthetic
gene clusters might be activated have recently led to the discovery of global regulators with a role in
controlling an array of biosynthetic gene clusters. One of these regulators is ScmR, an LTTR, which
has been shown to be involved in the production of various secondary metabolites in B. thailandensis
E264. ScmR is conserved in B. thailandensis (BTH_I1403) with orthologs in B. pseudomallei and B. mallei.
The scmR promoter contains a lux box, and gene expression was shown to be about two-fold greater
when the cells were grown to higher cell density [16,48,81]. Moreover, no activation of scmR was seen
Antibiotics 2019, 8, 160 10 of 19
in a mutant strain that was deleted for all three btaI genes, and therefore deficient in AHL synthesis.
Similarly, a B. pseudomallei Bp82 triple btaI mutant exhibited ~3-fold lower scmR transcript levels when
compared to wild type. Interestingly, the B. thailandensis triple btaI mutant featured an increased
production of cryptic secondary metabolites, as also seen in the ∆scmR strain, which suggests that
ScmR—and therefore production of some secondary metabolites—is regulated by quorum sensing.
Further, production of AHLs is drastically reduced in the ∆scmR strain, indicating reciprocal regulation
of AHL synthesis by ScmR. In the B. thailandensis ∆scmR strain, 13 of the >20 predicted biosynthetic
gene clusters in B. thailandensis were differentially regulated [16]. We will focus on the role of ScmR in
regulation of some of the compounds that are discussed above.
The inactivation of scmR leads to a 7- to 13-fold upregulation of genes in the bta cluster, indicating
that ScmR represses the production of Bactobolin [16]. The bta gene cluster is locally activated by BtaR2,
which is induced by AHLs. AHLs are produced at a higher cell density and they serve to activate both
BtaR2 and ScmR. The repression of genes in the bta cluster by ScmR could therefore be achieved by
ScmR binding directly to the btaI2 promoter and repressing transcription, consistent with the ~5-fold
increased expression of btaI2 in ∆scmR, forming a negative feedback loop that is designed to limit
bactobolin production by attenuating activation by the AHL-dependent BtaR2 (Figure 3). Recently,
a proteomic profiling of B. thailandensis during host infection revealed that ScmR is overexpressed
in host-associated bacteria; while nine of 11 proteins encoded by genes that are repressed by ScmR
were detected at lower levels, as expected, a Bactobolin biosynthetic enzyme was an exception. BtaC,
encoded by BTH_II1224, was overproduced during infection. This suggests that, at least under infection
conditions, Bactobolin synthesis is not solely determined through ScmR-mediated transcriptional
repression [82].
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scmR expression has been shown to be higher in presence of AHLs. Thus, the decrease in Capistruin
production that was observed as cells enter stationary phase might be due to more efficient repression
of Capistruin biosynthetic genes by ScmR [16]. Whether ScmR directly controls the Capistruin gene
cluster or whether it controls the expression of a cluster-specific regulator remains to be determined.
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The metabolomics analysis showed 61-fold increased production of Burkholdac A in ∆scmR cells,
and the corresponding transcriptome analysis revealed 50- to 135-fold upregulation of the various
genes in the bhc cluster [16]. Further, the complementation of the ∆scmR strain resulted in reduced
production of Burkholdac, as seen in wild type cells, which indicated that ScmR represses the bhc gene
cluster. Among the genes that were upregulated in ∆scmR cells is BTH_I2369 (bhcM), encoding the
AraC-family activator of the bhc gene cluster, BhcM. The repression of the bhc cluster by ScmR can
therefore be explained by its repression of bhcM, possibly by direct binding to its promoter, resulting
in failure to produce an essential activator. As AHLs are produced at higher cell density even under
normal laboratory settings, which leads to increased production of ScmR and repression of bhcM,
this would result in little to no production of Burkholdacs under these conditions.
The regulation of Malleilactone production by ScmR seems to be more complex. The metabolomics
analysis of ∆scmR cells showed 210-fold overproduction of Malleilactone A, previously shown to be
essential for the bacteria to cause infection in C. elegans. This overproduction was supported by the 8-
to 18-fold upregulation of the different genes in the mal gene cluster and by the ~90% worm killing in a
span of just 20 minutes when only ~5% of the worms were killed by wild type B. thailandensis [16].
Complementing the ∆scmR strain with plasmid-encoded scmR resulted in diminished production of
Malleilactone, which verifies that ScmR acts as a repressor of Malleilactone synthesis. MalR has been
established as an essential activator of the mal gene cluster, yet no change in expression of malR was
noticed in the ∆scmR cells. This led the authors to the suggestion that ScmR possibly competes with
MalR for binding to the mal promoter or that the accumulation of an unknown molecule only occurs
in ∆scmR cells and functions as a MalR coinducer to activate the mal gene cluster further; we favor
the first interpretation as no coinducers for MalR have been suggested in other studies. As discussed
below, the global regulator MftR represses the mal gene cluster by also repressing the malR gene,
which suggests an even more complex regulatory network. In a B. pseudomallei Bp82 ∆scmR strain,
only ~4-fold increased production of Malleilactone was reported as compared to wild type cells, and
the production was reduced to wild type levels upon complementing the mutant. In B. pseudomallei
Bp82, malR expression was reported to modestly increase in a mutant deficient in AHL synthesis and
malR transcript levels were two-fold higher in a ∆scmR strain, but only when cells were grown to late
stationary phase and not in exponential or early stationary phase [16,19]. While the change in malR
expression in the AHL mutant would be consistent with repression of malR by the quorum-sensing
activated ScmR, the growth phase-dependent malR expression in ∆scmR cells points to regulation by a
different mechanism.
3.2. Major Facilitator Transport Regulator (MftR)
B. thailandensis encodes 12 annotated MarR (Multiple Antibiotic Resistance Regulator) homologs,
all of which are conserved in B. mallei and B. pseudomallei [83]. Members of the MarR family are
transcription factors that are ubiquitous in the domains bacteria and archaea, and they have been
shown to regulate various biological functions, such as response to environmental stress (for instance,
antibiotic and oxidative stress or a change in pH), regulation of genes that are involved in virulence,
and catabolism of aromatic compounds [84–86]. The genomic locus in which mftR, BTH_I2391 in
B. thailandensis, is divergently oriented to the mftP-fenI operon (BTH_I2392 and BTH_2393) is conserved
across members of the Bpc. MftR is a MarR homolog, while MftP (Major Facilitator Transport Protein)
encodes an efflux pump and FenI is a predicted glycosyl hydrolase. MftR binds to the intergenic region
between these divergently oriented genes, thereby repressing the expression of both mftR as well as
the mftP-fenI operon [87].
MftR has been previously classified as a member of the MarR subfamily UrtR (Urate Responsive
Transcriptional Regulator) [87,88]. Urate and xanthine, which are products of purine metabolism [8,89],
bind MftR and attenuate its binding to DNA. Urate was predicted to bind MftR in a pocket that spans
the DNA-binding and dimerization regions of the protein, a prediction that was based on the structure
of the homologous urate-binding MarR protein HucR [87,90]. By binding in this pocket, the ligand is
Antibiotics 2019, 8, 160 12 of 19
predicted to reconfigure the disposition of DNA recognition helices to create a conformation that is
unfavorable for DNA binding. Urate is produced by host xanthine oxidase in response to bacterial
infection at levels that can exceed 200 µM [91], which suggests that MftR might regulate genes
upon host colonization. Indeed, determination of the MftR regulon by using an mftR knockout
mutant revealed differential expression of ~400 genes, such as genes that are involved in biosynthetic
processes, metabolism, and pathogenesis [17]. A total of 331 genes were upregulated, while 70 genes
were down-regulated in the ∆mftR strain, which suggests that MftR is a negative regulator of most
genes directly or indirectly under its control. Notably, a number of large biosynthetic gene clusters
encoding various secondary metabolites, which are not expressed under normal laboratory settings
were upregulated in the ∆mftR strain as well as when B. thailandensis was grown in media containing
urate. As urate attenuates MftR binding to DNA, this observation is consistent with MftR functioning
as a global repressor of these gene clusters, and it identifies urate as a common signal for the production
of secondary metabolites. A proteomics analysis of differential protein accumulation in host-associated
B. thailandensis showed a correlation between overproduced proteins and genes that are upregulated
on the addition of urate, in accord with this interpretation [82]. The gene encoding ScmR is among
those upregulated (2–3-fold) in the ∆mftR strain, whereas the expression of mftR is unaltered on the
deletion of scmR, which indicates that MftR acts upstream of ScmR [16,17].
As discussed above, secondary metabolite production might be controlled by quorum sensing via
AHL-activated expression of scmR. By contrast, MftR may be important for regulation of gene expression
under conditions of host infection that involve the activation of host xanthine oxidase and therefore
increased urate production. However, gene expression analyses indicate that these regulatory networks
are intricately intertwined. The expression of genes that are involved in quorum sensing (btaI2-btaR2,
btaI3-btaR3) as well as AHL levels are elevated in the ∆mftR strain, which directly implicates MftR in
the quorum sensing circuit [17]. Thus, scmR expression might be repressed either by direct binding
of MftR to the scmR promoter or—more likely—indirectly via the MftR-mediated regulation of AHL
synthesis (Figure 3). Genes encoding Bactobolin, including btaR2/btaI2, are upregulated ~15-fold on the
deletion of MftR or on the addition of urate, and scmR expression is modestly increased. This suggests
that the ScmR-mediated repression of btaI2 (and in turn the repression of the bta gene cluster) inferred
to occur during balanced growth is bypassed when MftR is absent or the inducing ligand for MftR
(urate) is present, and it is consistent with the overproduction of a Bactobolin biosynthetic enzyme
in host-associated B. thailandensis, even under conditions of increased ScmR levels [82]. As scmR
expression is increased in ∆mftR cells, a viable interpretation is that an activator of btaI2 becomes
abundant in the absence of MftR and competes with ScmR for binding; this activator could potentially
be BtaR2, the expression of which is markedly increased in ∆mftR cells [17].
ScmR represses the expression of the local activator BhcM that is required for expression of the bhc
gene cluster. Both scmR, bhcM and the Burkholdac biosynthetic gene cluster are upregulated ~two-fold
in the ∆mftR strain, an expression pattern that suggests a more complex mechanism for the control of
this gene cluster. The modestly increased expression of the Burkholdac biosynthetic genes in ∆mftR
cells may therefore also derive from the accumulation of an activator of bhcM that can compete with
ScmR for binding.
Expression of the mal and tha gene clusters that are involved in production of Malleilactone and
Thailandamide, respectively, are upregulated two- to four-fold in B. thailandensis deleted for mftR.
Genes encoding the local regulators MalR and ThaA are similarly upregulated in the ∆mftR strain,
which indicates the possibility of direct regulation of these regulators by MftR. Both of these secondary
metabolites and their respective gene clusters are upregulated in a ∆scmR strain, the mal gene cluster
in particular, but no upregulation of the respective local regulators was seen. Increased expression
of the mal gene cluster in ∆mftR cells could be explained by derepression of malR, which encodes an
activator, while the regulation by ScmR might entail a competition between ScmR and MalR for the
mal promoter, as noted above. A similar mode of regulation may pertain in the case of thaA, with ScmR
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more effectively competing with ThaA for the regulation of the tha gene cluster when thaA is repressed
by MftR.
Several genes that were upregulated in B. thailandensis ∆mftR cells encode proteins that are involved
in the production and transport of siderophores (Figure 3). This includes the gene clusters linked
to production of Pyoverdine (BTH_II0229-0234) and the Ornibactin-like siderophore Malleobactin
(BTH_I2414-2427). The mechanism of regulation of the Pyoverdine gene cluster remains unknown;
specifically, we note that the convergent gene encoding a predicted LTTR activator of this gene cluster
is not differentially expressed on the deletion of mftR [17]. The expression of genes in this gene cluster is
modestly (<two-fold) lower in ∆scmR cells, which suggests moderate activation by ScmR. By contrast,
the ECF sigma factor encoded as part of the Malleobactin gene cluster (BTH_I2427), which is predicted
to activate expression based on comparison to the P. aeruginosa homolog PvdS, is upregulated in ∆mftR
cells as well as in ∆scmR cells. Whether the gene encoding this sigma factor is directly or indirectly
regulated by either MftR and/or ScmR has not been reported. This ECF is unlikely to participate in the
activation of the Pyoverdine biosynthetic genes, as its upregulation in ∆scmR cells would have been
expected to result in an increased expression of this gene cluster.
4. Trimethoprim as an Inducer of Cryptic Biosynthetic Gene Clusters
Genome mining has advanced the discovery of cryptic biosynthetic gene clusters and prompted
efforts to optimize production of bioactive secondary metabolites. A variety of approaches, such as
changes in fermentation conditions (media composition, temperature, and pH), co-cultivation, deletion
of local regulators, and random insertional mutagenesis, have been successfully employed for the
isolation and characterization of specific compounds in Burkholderia spp. For instance, production
of Capistruin was greatly enhanced by growing B. thailandensis in M20 medium at 42 ◦C, while the
isolation of Thailanstatin was optimized by growing cells in defined fermentation medium [35,36,73,74].
The production of siderophores was favored by growing the bacteria in iron deficient media or by
cocultivation, and Malleilactone and Thailandamide were isolated as a result of an inducible promoter
exchange strategy [15,44,71,92]. Such approaches have been inspired by the successful production of
bioactive compounds from streptomycetes, which are well known as sources of clinically relevant
compounds. In these species, strain development and metabolic engineering approaches have also
been implemented for the improved production of select compounds [93]. While promising, metabolic
engineering remains challenging, due to unintended consequences of competing pathways or the
accumulation of toxic pathway intermediates.
In general, engineering approaches, including expression in heterologous hosts, have focused on
the production of specific compounds. In contrast, chemical elicitors that create a stressful environment
for the bacteria have the potential to induce the expression of multiple biosynthetic gene clusters.
The activation of cryptic gene clusters by small molecules or ligands may not only increase the
yield of individual compounds, but it is also a time and cost-saving technique by comparison to the
more laborious culture optimization or systems metabolic engineering approaches [94,95]. Notably,
a recent study that was focused on discovering novel elicitors of cryptic biosynthetic gene clusters
in B. thailandensis found that, among the 640 candidates tested, a sub-lethal dosage of the antibiotic
trimethoprim was the most potent elicitor [13]. It should be noted that a cocktail of trimethoprim and
sulfamethoxazole (Co-trimoxazole) is a therapeutic drug prescribed for the treatment of Burkholderia
infections [96,97]. Metabolomic profiling of cells that were treated with trimethoprim showed an
upregulation of over 100 compounds, including molecules related to Capistruin, Malleilactone,
Burkholdac, Thailandamide, and Bactobolin. Trimethoprim is a dihydrofolate reductase inhibitor,
which prevents the conversion of dihydrofolate to tetrahydrofolate, a one-carbon donor that is essential
in a variety of biosynthetic reactions, including the production of glycine, methionine, thymidine, and
purines [98]. For trimethoprim to bind all of the structurally different, pathway-specific regulators of
these cryptic biosynthetic gene clusters to induce gene expression would be unlikely. A more plausible
scenario would be for trimethoprim or a metabolite that accumulates in cells treated with this antibiotic
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to modulate the function of a global regulator. Indeed, a correlation exists between the compounds that
were detected on the addition of trimethoprim and the gene clusters upregulated when B. thailandensis
is grown in media with urate added. However, for MftR, it has already been shown that trimethoprim
does not directly bind to modulate DNA binding, and neither does 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR), an intermediate in de novo purine biosynthesis shown to accumulate in the
presence of trimethoprim [13,17]. Thus, the inducing ligand, which accumulates in cells grown with
trimethoprim, has yet to be discovered.
5. Conclusions and Future Outlook
Secondary metabolites confer a competitive advantage to bacteria in a hostile environment,
including the inhospitable environment that is created by host defenses, yet the mechanisms that
regulate their production have not been completely deciphered. The gene clusters that encode enzymes
responsible for the production of these secondary metabolites, whether being harmful virulence factors
or novel compounds with potential clinical activity, such as antibiotics, generally remain silent or
cryptic to conserve cellular resources. Understanding how the expression of these gene clusters is
elicited could shed light on mechanisms of pathogenicity as well as advance the discovery of novel
beneficial compounds. The identification of global regulators, which control cryptic biosynthetic gene
clusters, has opened a possible path towards achieving these goals.
Global regulators have previously been shown to be involved in the regulation of specialized genes,
such as those that are involved in pathogenesis, quorum sensing, and biofilm formation. Increased
biofilm formation, which also aids in bacterial antibiotic resistance, is a characteristic of the ∆scmR
strain. In a similar vein, increased anaerobiosis has been reported for the ∆mftR strain, a metabolic
state that is critical for the survival of bacterial species in an oxygen-deprived environment, such as
the interior of a biofilm and abscesses that are caused by infection. A role for both ScmR and MftR
in virulence is further supported by their regulation of genes encoding enzymes that are responsible
for the production of siderophores, which become critical in the iron-deficient environment inside a
host [16,17,99,100]. These findings not only suggest that global regulators can control bacterial fitness
in a host environment and increase their antibiotic resistance, but they also suggest global regulators as
suitable targets for drugs. A recent study in P. aeruginosa showed that the global regulator MvfR (also
known as PqsR), an LTTR, is involved in biofilm formation. A drug (M64) targeting MvfR interfered
with biofilm formation of P. aeugronoisa and increased the antibiofilm activity of other antibiotics when
used in conjunction with M64 [101].
The secondary metabolites that are discussed above likely represent just the tip of the iceberg
and additional, novel secondary metabolites isolated from Burkholderia spp. await characterization.
Inactivation of the global regulators ScmR and MftR is associated with remarkable changes in secondary
metabolite production and a corresponding induction of biosynthetic gene clusters. Based on these
observations, we predict that identifying global regulators in other bacterial species and understanding
their regulatory mechanisms through a combination of genome-wide transcriptomics, metabolomics,
and ChIP-Seq may enhance our chances of discovering potentially bioactive compounds as well as
novel drug targets for pathogenic strains.
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